PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT

PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT: PANDORE-PANC-IPC 2021-082

The study consists of a 25 ml blood sample collection:

• Before the start of treatment
• Approximately 2 months after the start of induction chemotherapy
• At the end of induction chemotherapy
• Prior to local treatment (radiotherapy, surgery)
• At the time of tumor progression

Collection of tumor material:

• During the initial diagnostic biopsy
• On the operating room in case of surgery
• At tumor biopsy in case of recurrence or progression (optional) As well as the completion of a questionnaire at inclusion.

Inclusion Criteria:

• Non-metastatic pancreatic adenocarcinoma that is not immediately resectable (borderline and locally advanced tumors according to the NCCN 2020 classification)
• No previous treatment with surgery or chemotherapy
• Age > 18 years
• General condition WHO 0-2 (patient whose general condition can allow medical treatment or surgery)
• Therapeutic management at the Paoli-Calmettes Institute
• Signature of the informed consent specific to the PANDORE-PANC study
• Patient affiliated to a social security system or benefiting from such a system

Exclusion Criteria:

• Metastatic disease
• Pancreatic tumor of a histological type other than adenocarcinoma
• Other tumor under treatment or for which treatments have been completed for < 1 year
• Pregnant or breastfeeding women
• Person in an emergency situation
• Person of legal age under legal protection (guardianship, curatorship or safeguard of justice) or unable to give consent.